Neuronal apoptosis as a therapeutic target in neurodegenerative disease

Bibliography

• Selective Neuronal Death (CIBA Foundation Symposium 126). Wisniewski HM (Ed.), Wiley, Chichester, UK (1987).
   Google Scholar
• LARNER AJ, SOFRONIEW MV: Mechanisms of cellular damage and recovery. In: Handbook of neurological rehabilitation. Greenwood RJ et al. (Eds.), Churchill Living-stone, Edinburgh, UK (2000) [In Press].
   Google Scholar
• KERR JFR, WYLLIE AH, CURRIE AR: Apoptosis: a basic biological phenomenon with wide-ranging implica-tions in tissue kinetics. Br. J. Cancer (1972) 26:239–257.
   PubMed Web of Science ®Google Scholar
• THOMPSON CB: Apoptosis in the pathogenesis andtreatment of disease. Science (1995) 267:1456–1462.
   PubMed Web of Science ®Google Scholar
• HETTS SW: To die or not to die. An overview ofapoptosis and its role in disease. JAMA (1998) 279:300–307.
   Google Scholar
• BREDESEN DE: Neural apoptosis. Ann. Neurol. (1995)38:839–851.
   PubMed Web of Science ®Google Scholar
• STEFANIS L, BURKE RE, GREENE LA: Apoptosis inneurodegenerative disorders. CUIT. Opin. Neurol. (1997) 10:299–305.
   PubMed Web of Science ®Google Scholar
• CHARRIAUT-MARLANGUE C, AGGOUN-ZOUAOUI D, REPRESA A, BEN-ART Y: Apoptotic features of selective neuronal death in ischemia, epilepsy and gp120 toxicity. Trends NeuroscL (1996) 1 9 :109–114.
   Google Scholar
• WYLLIE A, KERR JF, CURRIE AR: Cell death: the signifi-cance of apoptosis. Int. Rev. Cytol. (1980) 68:251–306.
   PubMedGoogle Scholar
• •A useful summary of the morphological aspects of apoptosis by the authors who first defined the process.
   Google Scholar
• JACOBSON MD, BURNE JF, RAFF MC: Programmed cell death and bc1-2 protection in the absence of a nucleus. EMBO J (1994) 13: 1899-1910.
   Google Scholar
• •Study showing that a nucleus, and hence DNA fragmenta-tion, is not essential for apoptosis to occur.
   Google Scholar
• MARCHETTI P, SUSIN SA, DECAUDIN D et al: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. (1996) 56:2033–2038.
   PubMedGoogle Scholar
• BONFOCO E, KRAINE D, ANCARCRONA M, NICOTERA P,LIPTON SA: Apoptosis and necrosis: two distinct events induced respectively by mild and intense insult with NMDA or nitric oxide/superoxide in cortical cell cultures. Proc. Nati Acad. Sci. USA (1995) 91:7162–7166.
   Google Scholar
• PORTERA-CAILLIAU C, PRICE DL, MARTIN LI Excitotoxicneuronal death in the immature brain is an apoptosis-necrosis morphological continuum. J. Comp. Neurol (1997) 378:70–87.
   PubMedGoogle Scholar
• PORTERA-CAILLIAU C, PRICE DL, MARTIN LI Non -NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J Comp. Neurol. (1997) 378:88–104.
   PubMed Web of Science ®Google Scholar
• NAGATA S: Fas ligand-induced apoptosis. Ann. Rev. Genetics (1999) 33:29–55.
   PubMed Web of Science ®Google Scholar
• COTMAN CW, CRIBBS DH, SU JH: Apoptosis andAlzheimer's disease: a self-assembly and the initiation of apoptosis by plasma membrane receptor cross-linking. In: Alzheimer's disease: from molecular biology to therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston (1996):99–106.
   Google Scholar
• ESTUS S, ZAKS WJ, FREEMAN RS, GRUDA M, BRAVO R,JOHNSON E: Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. j Cell Biol. (1994) 126:1717–1727.
   Google Scholar
• HAM J, BABIJ C, WHITEFIELD J, PFARR CM, LALLEMAND J,YANIV M, RUBIN LL: A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron (1995) 14:927–939.
   PubMed Web of Science ®Google Scholar
• MAH SP, ZHONG LT, LIU Y, ROGHANI A, EDWARDS RH,BREDESEN DE: The proto-oncogene bc1-2 inhibits apoptosis in PC12 cells. J. Neurochem. (1993) 60:1183–1186.
   PubMed Web of Science ®Google Scholar
• GARCIA I, MARTINOU I, TSUJIMOTO Y, MARTINOU J-C:Prevention of programmed cell death of sympathetic neurons by the bc1-2 proto-oncogene. Science (1992) 258:302–304.
   PubMed Web of Science ®Google Scholar
• LEWIS J, OYLER GA, UENO K et al.: Inhibition of virus-induced neuronal apoptosis by Bax. Nature Med. (1999) 5:832–835.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-GARCIA M, GARCIA I, DING L et al: bcl-x isexpressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proc. Natl. Acad. ScL USA (1995) 92:4304–4308.
   PubMedGoogle Scholar
• OLTVAI ZN, MILLIMAN CL, KORSMEYER SJ: bc1-2 hetero-dimerizes in vivowith a conserved homolog, bax, that accelerates programmed cell death. Cell (1993) 74:609–619.
   PubMed Web of Science ®Google Scholar
• LI JM, SHORE GC: Reversal of the orientation of anintegral protein of the mitochondrial outer membrane. Science (1992) 256:1815–1817.
   PubMed Web of Science ®Google Scholar
• ZOU H, HENZEL WJ, LIU X, LUTSCHG A, WANG X: Apaf-1,a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell (1997) 90:405–413.
   Google Scholar
• BEHRENS MM, STRASSER U, KOH J-Y, GWAG BJ, CHOIDW: Prevention of neuronal apoptosis by phorbol ester-induced activation or protein kinase C blockade of p38 mitogen-activated protein kinase. Neuroscience (1999) 94:917–927.
   PubMedGoogle Scholar
• MAZZONI IE, SAID FA, ALOYZ R, MILLER FD, KAPLAN D:Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway. J NeuroscL (1999) 19:9716–9727.
   PubMedGoogle Scholar
• ROY N, MAHADEVAN MS, MCLEAN M et al: The gene forneuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell (1995) 80:167–178.
   PubMed Web of Science ®Google Scholar
• •One of the earliest reports implicating an apoptosis regula-tory protein in the pathogenesis of a human neurodegenera-tive disorder.
   Google Scholar
• JANICKE RU, SPRENGART ML, WATI MR, PORTER AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Biol. Chem. (1998) 273:9357–9360.
   Google Scholar
• KUIDA K, ZHENG TS, NA S et al.: Decreased apoptosis inthe brain and premature lethality in CPP32-deficient mice. Nature (1996) 384:368–372.
   PubMed Web of Science ®Google Scholar
• ENARI M, TALANIAN RV, WONG WW, NAGATA S: Sequen-tial activation of ICE-like and CPP-like proteases during Fas-mediated apoptosis. Nature (1996) 380:723–726.
   PubMed Web of Science ®Google Scholar
• MILLIGAN CE, PREVETTE D, YAGINUMA H et al: Peptideinhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron (1995) 15:385–393.
   PubMed Web of Science ®Google Scholar
• •A study showing that ICE inhibition blocks apoptosis.
   Google Scholar
• OPPENHEIM RW: Cell death during development of thenervous system. Ann. Rev. NeuroscL (1991) 14:453–501.
   PubMed Web of Science ®Google Scholar
• LEBLANC A: Apoptosis and Alzheimer's disease. In:Molecular Mechanisms of Dementia. Wasco W, Tanzi RE (Eds.), Humana, Totawa, NJ, USA (1997):57–71.
   Google Scholar
• CHANG G-Q, HAO Y, WONG F: Apoptosis: finalcommon pathway of photoreceptor death in rd, rds and rhodopsin mutant mice. Neuron (1993) 11:595–605.
   PubMedGoogle Scholar
• LOO DT, COPANI A, PIKE CJ, WHITTEMORE ER, WALENCEWICZ AJ, COTMAN CW: Apoptosis is induced by I3-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. ScL USA (1993) 90:7951–7955.
   PubMed Web of Science ®Google Scholar
• •First study to implicate apoptosis as a feature of AP-induced neurotoxicity.
   Google Scholar
• BEHL C, DAVIS JB, LESLEY R, SCHUBERT D: Hydrogenperoxide mediates amyloid P protein toxicity. Cell (1994) 77:817–827.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Neurite growth-inhibitory properties ofamyloid I3-peptides in vitro: A1325-35, but not AI31-40, is inhibitory. NeuroscL Res. Commun. (1997) 20:147–155.
   Google Scholar
• SELZNICK LA, ZHENG TS, FLAVELL RA, RAKIC P, ROTHKA: Amyloid I3-induced neuronal death is Bax-dependent but caspase-independent. J. Neuropa-thol. Exp. Neurol. (2000) 59:271–279.
   PubMedGoogle Scholar
• STROSZNAJDER JB, JESKO H, STROSZNAJDER RP: Molecular mechanism of amyloid beta peptides evoked alteration of DNA-bound poly(ADP-ribose) polymerase in adult and aged brain. Neurobiol Aging (2000) 21 (Supp1.1):S253 (Abstract 1155).
   Google Scholar
• ANDERSON AJ, SU JH, COTMAN CW: DNA damage andapoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area and effect of postmortem delay. J NeuroscL (1996) 16:1710–1719.
   PubMed Web of Science ®Google Scholar
• ANDERSON AJ, CUMMINGS BJ, COTMAN CW: Increasedimmunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology. Exp. Neurol. (1994) 125:286–295.
   PubMed Web of Science ®Google Scholar
• SU JH, SATOU T, ANDERSON AJ, COTMAN CW: Up-regulation of Bc1-2 is associated with neuronal DNA damage in Alzheimer's disease. NeuroReport (1996) 7:437–440.
   PubMedGoogle Scholar
• SCHEUNER D, ECKMAN C, JENSEN M et al.: Secretedamyloid I3-protein similar to that in the amyloid plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. (1996) 2:864–870.
   PubMed Web of Science ®Google Scholar
• YAMATSUJI T, MATSUI T, OKAMOTO T et al.: G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science (1996) 272:1349–1352.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B, IWASAKI K, VITO P et al.: PS2 participates in cellular apoptosis: constitutive activity conferred by Alzheimer mutation. Science (1996) 274: 1710-1713.
   Google Scholar
• WEIDEMANN A, PALIGA K, DORRWANG U et al: Cleavage of the Alzheimer's disease amyloid precursor protein during apoptosis by activated caspases. In: Alzheimer's Disease, and Related Disorders: Etiology, Pathogenesis and Therapeutics. Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds.), Wiley, Chichester, UK (1999):391–396.
   Google Scholar
• KIM T-W, PETTINGELL WH, JUNG Y-K, KOVACS DM, TANZI RM: Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science (1997) 277:373–376.
   PubMedGoogle Scholar
• GERVAIS FG, XU D, ROBERTSON GS et al.: Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-13 precursor protein and amyloidogenic A13 peptide formation. Cell (1999) 97:395–406.
   PubMed Web of Science ®Google Scholar
• ROHRIG S, BROCKHAUS M, STEINER H et al.: Role of presenilin processing and caspases for amyloid 13-peptide generation and NOTCH signaling. In: Alzheimer's Disease, and Related Disorders: Etiology, Pathogenesis and Therapeutics. Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds.), Wiley, Chichester (1999):353–362.
   Google Scholar
• FASULO L, VISINTIN M, NOVAK M, CATTANEO A: Tau truncation in Alzheimer's disease: expression of a fragment encompassing PHF core tau induces apoptosis in COS cells. Alzheimer's Reports (1998) 1:25–31.
   Google Scholar
• LARNER AJ: Tau protein as a therapeutic target inAlzheimer's disease and other neurodegenerative disorders. Exp. Opin. Ther. Patents (1 9 9 9) 9(101359–1370.
   Google Scholar
• GUO Q, FU W, XIE J et al.: Par-4 is a mediator of neuronaldegeneration associated with the pathogenesis of Alzheimer's disease. Nature Med. (1998) 4:957–962.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, SHIMOHAMA S, KAMOSHIMA W et al.: Alteration of proteins regulating apoptosis, Bc1-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. (1998) 780:260–269.
   PubMed Web of Science ®Google Scholar
• DESJARDINS P, LEDOUX S: Expression of ced-3 andced-9 homologs in Alzheimer's disease cerebral cortex. Neurosci. Lett. (1998) 244:69–72.
   PubMedGoogle Scholar
• SELZNICK LA, HOLTZMAN DM, HAN BH et al.: In situimmunodetection of neuronal caspase-3 activation in Alzheimer's disease. J. Neuropathol. Exp. Neurol. (1999) 58:1020–1026.
   PubMed Web of Science ®Google Scholar
• DE LA MONTE SM, SOHN YK, WANDS JR: Correlates of p53- and Fas (CD9 5)-mediated apoptosis in Alzheimer's disease. J Neurol. Sci. (1997) 152:73–83.
   PubMedGoogle Scholar
• YANG F, SUN X, BEECH W et al.: Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma neurons and plaque associated neurons and microglia in Alzheimer's disease. Am. J Pathol. (1998) 1 52:379–389.
   Google Scholar
• MITCHELL IJ, LAWSON S, MOSER B et al.: Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience (1994) 63:1–5.
   PubMedGoogle Scholar
• ZIV I, ZILKHA-FALB R, OFFEND, SHIRVAN A, BARZILAI A,MELAMED E: levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease. Mov. Disord. (1997) 12:17–23.
   PubMed Web of Science ®Google Scholar
• •An alarming report suggesting that levodopa, the standard treatment for PD, may accelerate the pathogenetic apoptosis of nigrostriatal cells; this possibility remains to be confirmed or refuted.
   Google Scholar
• FALL CP, BENNETT JP, JR.: Characterization and timecourse of MPPtinduced apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. (1999) 55:620–628.
   Google Scholar
• WU Y, BLUM D, NISSOU MF, BENABID AL, VERNA JM:Unlike MPP+, apoptosis induced by 6-hydroxy dopamine in PC12 cells is independent of mitochon-drial inhibition. Neurosci. Lett. (1996) 221:69–71.
   PubMedGoogle Scholar
• WOODGATE A, MACGIBBON G, WALTON M, DRAGUNOW M: The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res. Mol. Brain Res. (1999) 69:84–92.
   PubMedGoogle Scholar
• HE Y, LEE T, LEONG SK: 6-hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res. (2000) 858:163–166.
   PubMedGoogle Scholar
• OFFEND, BEART PM, CHEUNG NS et al.: Tr an sgen ic mice expressing human Bc1-2 in their neurons are resistant to 6-hydroxydopamine and 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA (1998) 95:5789–5794.
   PubMedGoogle Scholar
• WULLNER U, KORNHUBER J, WELLER M et al.: Cell deathand apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathol. Berl. (1999) 97:408–412.
   PubMed Web of Science ®Google Scholar
• DE LA MONTE SM, SOHN YK, GANJU N, WANDS JR: p53-and CD95-associated apoptosis in neurodegenerative disease. Lab. Invest. (1998) 78:401–411.
   PubMedGoogle Scholar
• ANSARI KS, YU PH, KRUCK TP, TATTON WG: Rescue ofaxotomized rat facial motoneurons by R (-) deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci. (1993) 13:4042–4053.
   PubMed Web of Science ®Google Scholar
• •An interesting report that the MAO-B inhibitor deprenyl, known to delay the need for levodopa in PD, may have other effects independent of MAO-B inhibition which block apoptosis.
   Google Scholar
• GELOWITZ DL, PATERSON IA: Neuronal sparing andbehavioral effects of the antiapoptotic drug, (-) deprenyl, following kainic acid administration. Pharmacol. Biochem. Behav. (1999) 62:255–262.
   PubMedGoogle Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlledtrial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl. J. Med. (1997) 336:1216–1222.
   PubMed Web of Science ®Google Scholar
• SIMIC G, SESO-SIMIC D, LUCASSEN PJ et al.: Ultrastruc-tural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann disease. J. Neuropa-thol. Exp. Neurol. (2000) 59:398–407.
   PubMedGoogle Scholar
• ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutationsin Cuan superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59–62.
   PubMed Web of Science ®Google Scholar
• RABIZADEH S, GRALLA EB, BORCHELT DR et al.:Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc. Nati Acad. Sci. USA (1995) 92:3024–3028.
   PubMed Web of Science ®Google Scholar
• KOSIC V, JACKSON-LEWIS V, DE BILBAO F, DUBOIS- DAUPHIN M, PRZEDBORSKI S: Bc1-2 : prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science (1997) 277:559–562.
   PubMedGoogle Scholar
• FRIEDLANDER RM, BROWN RH, GAGLIARDINI V, WANG J, YUAN J: Inhibition of ICE slows MS in mice. Nature (1997) 388:31. [ERRATUM: Nature (1998) 392:560.]
   Google Scholar
• •Study showing delayed disease progression in a transgenic animal model of human fALS when treated with a panspe-cific ICE inhibitor. An example of the kind of study which will be necessary to suggest that clinical trials of apoptosis inhibitors are appropriate.
   Google Scholar
• MARTIN LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. (1999) 58:459–471.
   PubMed Web of Science ®Google Scholar
• PORTERA-CAILLIAU C, HEDREEN JC, PRICE DL, KOLIATSOS VE: Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. NeuroscL (1995) 15:3775–3787.
   PubMed Web of Science ®Google Scholar
• MIYASHITA T, MATSUI J, OHTSUKA Y et al: Expression of extended polyglutamine sequentially activates initiator and effector caspases. Biochem. Biophys. Res. Commun. (1999) 257:724–730.
   PubMedGoogle Scholar
• SANCHEZ I, XU CJ, JUO P, KAKIZAKA A, BLENIS J, YUAN J:Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron (1999) 22:623–633.
   PubMed Web of Science ®Google Scholar
• SANDOU F, FINKBEINER S, DEVYS D, GREENBERG ME:Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 95:55–66.
   PubMedGoogle Scholar
• MITCHELL IJ, COOPER AJ, GRIFFITHS MR, BARBER DJ: Phencyclidine and dexamethasone induce apoptosis of a subpopulation of striatal neurons: a neural substrate for psychosis? Neuroscience (1998) 84:489–501.
   PubMed Web of Science ®Google Scholar
• CHEN M, ONA VO, LI M et al.: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Hunting-ton's disease. Nature Med. (2000) 6:797–801.
   PubMedGoogle Scholar
• FORLONI G, ANGERETTI N, CHIESA R et al.: Neurotox-icity of a prion protein fragment. Nature (1993) 362:543–546.
   PubMed Web of Science ®Google Scholar
• LEBLANC A: Unraveling the controversy of human prion protein diseases. In: Handbook of the Aging Brain. Wang E, Snyder DS (Eds.), Academic, San Diego, USA (1998):201–221.
   Google Scholar
• PROUT KA, LARNER AJ: Emerging therapeutic possibili-ties in prion diseases: patents 1993-1998. Exp. Opin. Ther. Patents (1998) 8 (9) :1099–1108.
   Web of Science ®Google Scholar
• GRAY F, CHRETIEN F, ADLE-BIASSETTE H et al: Neuronal apoptosis in Creutzfeldt-Jakob disease. J Neuropathol. Exp. Neurol. (1999) 58:321–328.
   PubMed Web of Science ®Google Scholar
• DORANDEU A, WINGERTSMANN L, CHRETIEN F et al.: Neuronal apoptosis in fatal familial insomnia. Brain Pathol. (1998) 8:531–537.
   PubMedGoogle Scholar
• PEROVIC S, SCHRODER HC, PERGANDE G, USHIJIMA H,MULLER WE: Effect of flupirtine on Bc1-2 and glutathione level in neuronal cells treated in vitrowith the prion protein fragment (PrP106-126). Exp. Neurol (1997) 147:518–524.
   PubMed Web of Science ®Google Scholar
• OTTO M, BOEKHOFF I, RATZKA P et al: First therapeuticexperience with flupirtine in patients with Creutzfeldt-Jakob disease. J. Neurol. (1998) 245:486 [Abstract P549].
   Google Scholar
• SARGOVI HU, BURGESS K: Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents. Exp. Opin. Ther. Patents (1999) 9 (6):737–751.
   Google Scholar
• SATO T, IRIE S, KITADA S, REED JC: FAP-1: a proteintyrosine phosphatase that associates with Fas. Science (1995) 268:411–415.
   PubMed Web of Science ®Google Scholar
• KELLER JN, KINDY MS, HOLTSBERG FW et al: Mitochon-drial manganese superoxide dismutase prevents neuronal apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation and mitochondrial dysfunction. J. NeuroscL (1998) 18:687–697.
   PubMed Web of Science ®Google Scholar
• YAN SD, FU J, SOTO C et al.: An intracellular protein thatbinds amyloid-13 peptide and mediates neurotoxicity in Alzheimer's disease. Nature (1997) 389:689–695.
   PubMed Web of Science ®Google Scholar
• XIA Z, DICKENS M, RAINGEAUD J, DAVIS RJ, GREENBERGME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 270:1326–1331.
   PubMed Web of Science ®Google Scholar
• LARNER AJ, ROSSOR MN: Alzheimer's disease: towardstherapeutic manipulation of the amyloid precursor protein and amyloid13-peptides. Exp. Opin. Ther. Patents (1997) 7(101115–1127.
   Google Scholar
• Engraftable human neural stem cells. Exp. Opin. Ther. Patents (2000) 10(4):493–496.
   Google Scholar
• THORNBERRY NA, BULL HG, CALAYCAY JR et al.: A novel heterodimeric cysteine protease is required for interleukin-113 processing in monocytes. Nature (1992) 356:768–774.
   PubMed Web of Science ®Google Scholar
• MUZIO M, CHINNAIYAN AM, KISCHKEL FC et al.: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell (1996) 85:817–827.
   PubMed Web of Science ®Google Scholar
• HOLTZMAN DM, DESHMUKH M: Caspases: a treatment target for neurodegenerative disease? Nature Med. (1997) 3:954–955.
   Google Scholar
• SCHULZ JB, WELLER M, MOSKOWITZ MA: Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol (1999) 45:421–429.
   PubMed Web of Science ®Google Scholar
• CATES GA, BRICKENDEN AM, SANWAL BD: Possible involvement of a cell surface glycoprotein in the differentiation of skeletal myoblasts. J Biol. Chem. (1984) 259:2646–2650.
   PubMed Web of Science ®Google Scholar
• DUAN H, DIXIT VM: RAIDD is a new 'death' adaptor molecule. Nature (1997) 385:86–89.
   PubMed Web of Science ®Google Scholar
• PERUTZ MF: Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. (1999) 24:58–63.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN BA, NELSON D, SILVER IA, ERECINSKA M, CHESSELET MF: Methylmalonate toxicity in primary neuronal cultures. Neuroscience (1998) 86:279–290.
   PubMedGoogle Scholar
• BURNS A, ROSSOR M, HECKER J et al: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. (1999) 10:237–244.
   PubMed Web of Science ®Google Scholar
• FOLSTEIN MF, FOLSTEIN FE, MCHUGH PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. (1975) 12:180–198.
   Google Scholar
• SOTO C, KINDY MS, BAUMANN M, FRANGIONE B: Inhibi-tion of Alzheimer's amyloidosis by peptides that prevent I3-sheet conformation. Biochem. Biophys. Res. Commun. (1996) 226:672–680.
   PubMed Web of Science ®Google Scholar
• SOTO C, KASCSAK RJ, SABORIO GP et al: Reversion of prion protein conformational changes by synthetic I3-sheet breaker peptides. Lancet (2000) 355:192–197.
   PubMed Web of Science ®Google Scholar
• KUWAHARA C, TAKEUCHI AM, NISHIMURA T et al: Prions prevent neuronal cell-line death. Nature (1999) 400:225–226.
   PubMed Web of Science ®Google Scholar
• •Study suggesting that the normal cellular isoform of PrP is anti-apoptotic.
   Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R et al: Alzheimer-type neuropathology in transgenic mice overex-pressing V717F I3-amyloid precursor protein. Nature (1995) 373:523–527.
   PubMed Web of Science ®Google Scholar
• Transgenic animal model for Alzheimer's disease. Exp. Opin. Ther. Patents (1998) 8(6):729–732.
   Google Scholar
• Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease. Exp. Opin. Ther. Patents (1999) 9 (2):201–204.
   Google Scholar
• LAFERLA FM, TINKLE BT, BIEBERICH CJ, HAUDENSCHILD CC, JAY G: The Alzheimer's AI3 peptide induces neurodegeneration and ap op totic cell death in transgenic mice. Nature Genet. (1995) 9:21–30.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB: Cell biology and transgenic models of prion diseases. In: Prion Diseases. Collinge J, Palmer MS. (Eds.), OUP, Oxford, UK (1997):130–162.
   Google Scholar
• JO M, KIM T-H, SEOL D-W et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med. (2000) 6:564–567.
   PubMedGoogle Scholar
• LARNER AJ: The cortical neuritic dystrophy of Alzheimer's disease: nature, significance and possible pathogenesis. Dementia (1995) 6:218–224.
   PubMedGoogle Scholar
• LU P-J, WULF G, ZHOU XZ, DAVIES P, LU KP: The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 399:784–788.
   PubMedGoogle Scholar
• DEIGNER H-P, HABERKORN U, KINSCHERF R: Apoptosis modulators in the therapy of neurodegenerative diseases. Exp. Opin. Invest. Drugs (2000) 9(4):747–764.
   PubMedGoogle Scholar
• NACHEV PC, LARNER AJ: Zinc and Alzheimer's disease. Trace Elements Electrolytes (1996) 13:55–59.
   Web of Science ®Google Scholar